Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its’ effectiveness with botulinum toxin injection

Abstract

Objectives:To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model.Materials and Methods:40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex.Results:Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%.Conclusion:Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in prostatic benign hyperplasia that needs to be verified in large randomized human experimental studies.

Transurethral Intraprostatic Botulinum Toxin-a Injection in Patients with Benign Prostatic Hyperplasia: A Case Series and Literature Review

“…Four experiments on adult male Sprague-Dawley rats showed atrophy and apoptosis of the prostate gland [10][11][12][13]. Two studies on Wistar rats also showed the same results [14,15]. Also in previous studies on canine models, researchers have shown decreases in the prostate size, but significant atrophy was shown in only one study [9,16].…”

Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study

“…Experimentally, Hsu et al [22] found that BoNT-A induces prostate apoptosis, down-regulation of α 1 a1-adrenergic receptors, and reduces contractile function of the prostate. Also, Ergün et al [39], using a rat model of BPH, detected decreases of estimated PV and its actual weight by~32.5% after BoNT-A injection and attributed this to induction of prostate apoptosis.…”